Personalizing
Cancer Treatment for Everyone

WEBINAR

Childhood Cancer
Precision in Pediatrics: Diagnosing and Curing Childhood Cancer

Caregivers, cancer patients, and loved ones, you can watch this webinar about childhood cancer by  Dr. Jason Freedman, Dr. Gerald Wertheim and Dr. Sarah Tasian.

If you missed the webinar, you can still watch the recording here.

 

Ask our doctors your questions about cancer
Panel of Doctors Answer Your Questions About Cancer

Caregivers, patients, and loved ones joined Dr. Belisario Arango and Dr. Arturo Loaiza-Bonilla on Monday, June 19, 12 pm EDT for this very informative and interactive question and answer panel format webinar. 

Our doctors answered participants questions submitted during the webinar and ones that have been sent to Massive Bio. 

Cancer Treatment Doctor
Bringing state-of-the-art precision cancer care Bringing state-of-the-art precision cancer care to rural communities

Bringing state-of-the-art precision cancer care was aired Tuesday, March 14 at 12:00 EDT. 

Dr. Belisario Arango covered the following topics:

Why there is a higher cancer prevalence in patients in rural areas?
What are the challenges delivering cancer care to patients? 
Where is the future of cancer care going?

VIEW ALL ARTICLES

PRESS RELEASES

Massive Bio at ACCC 44th Annual Meeting and Cancer Center Business Summit
Massive Bio attends, as well as sponsors the ACCC 44th Annual Meeting and Cancer Center Business Summit The Association of Community Cancer Centers (ACCC) empowers every member of the multidisciplinary cancer team to provide exceptional patient care.

Healthcare reform is undergoing a wave of radical change and disruptive innovation, with stakeholders transitioning to value-based care delivery models to reduce costs and improve quality of care. At the same time, leveraging advanced technologies, experimenting with various business models, and developing new relationships are changing the way that medicine is practiced.

J.P. Morgan (JPM) Healthcare Conference Insights
J.P. Morgan (JPM) Healthcare Conference Insights from Massive Bio Co-founder and CEO, Selin Kurnaz

Hello everyone! Another J.P. Morgan Healthcare Conference has come and gone. Overall, it was chaotic but productive for Massive Bio. There were no game changing learning experiences for our core which is precision oncology informatics services, maybe because we live and breathe this space every day. However, the necessity of Massive Bio increases everyday to streamline disparate clinical and genomic information and disparate stakeholders. Precision oncology needs a translator and accelerator more than ever to be mainstream. Massive Bio put precision oncology to “work” — organizes and harmonizes disparate knowledge into clinical utility. In any case, I have summarized our key take-aways from the conference in regards to our space, digital health and AI and overall healthcare. Hope you will find it as an enjoyable read and I am always happy to have a dialogue and attack healthcare issues with like minded people together. 

Happy Valentine's Day Savings
Happy Valentine's Day Offer

We continue to support you and your loved ones by sharing new savings. 

he American Turkish Society is pleased to announce the sixth class of
Massive Bio CEO chosen for 2017 Class of Young Society Leaders

The American Turkish Society is pleased to announce the sixth class of "Young Society Leaders," a group of 25 accomplished professionals with a demonstrated record of leadership ability and commitment to serve the U.S.-Turkish community at large.

VIEW ALL ARTICLES

IN THE NEWS

Expert Discusses Radiation Techniques, Genomic Testing in Prostate Cancer

Since the emergence of new data released in 2017, moderate hypofractionation has proven to be a quicker and efficacious method to administer radiation therapy to patients with prostate cancer.

 

Genetic Testing Becoming More Widespread in Ovarian Cancer, But Challenges Remain

Testing for genetic alterations has become an important step in the treatment of patients with ovarian cancer. Although much has been achieved, says Mike Janicek, MD, there needs to be more widespread use of genetic testing in order to push the field forward.

Latest clinical evidence and further development of PARP inhibitors in ovarian cancer

For several decades, the systemic treatment of ovarian cancer has involved chemotherapy, with the relatively recent addition of anti-angiogenic strategies given with chemotherapy and in the maintenance setting. In the past decade, numerous poly(ADP-ribose) polymerase (PARP)-inhibiting agents have been assessed.

 

How can we stop fat cells from fueling cancer?

Cancer cells constantly grow and divide, which means that they need a consistent energy supply. A new study looks at how cancer derives fuel from fat cells and finds a potential mechanism to starve the tumor of its nutrition.

 

VIEW ALL ARTICLES

PUBLISHED RESEARCH

Prognostic value of microRNAs in colorectal cancer: a meta-analysis

Numerous studies have shown that miRNA levels are closely related to the survival time of patients with colon, rectal, or colorectal cancer (CRC). However, the outcomes of different investigations have been inconsistent. Accordingly, a meta-analysis was conducted to study associations among the three types of cancers.

Harnessing the Perioperative Period to Improve Long-term Cancer Outcomes

The short perioperative period, spanning several days pre- and postsurgery, is now believed to have a nonproportionally large impact on long-term cancer outcomes (1,2). Numerous physiological responses to the newly discovered cancer and to surgical resection trigger pro-metastatic processes that can affect minimal residual disease (MRD; single tumor cells/micrometastases).

Portraits of genetic intra-tumour heterogeneity and subclonal selection across cancer types

Continued evolution in cancers gives rise to intra-tumour heterogeneity (ITH), which is a major mechanism of therapeutic resistance and therefore an important clinical challenge. However, the extent, origin and drivers of ITH across cancer types are poorly understood. Here, we extensively characterise ITH across 2,778 cancer whole genome sequences from 36 cancer types.

Massive Bio Announces First Patient Enrolled in Its Pivotal Global SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio, Inc., a leader in providing simplified and affordable access to precision oncology to cancer patients treated at community-based oncology practices, announced today that the first patient has been enrolled in a global registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool powered by a virtual tumor board (VTB) program. This registry will assess its clinical impact on world-wide patients with advanced cancer to facilitate clinical trial enrollment (CTE), as well as financial impact.

VIEW ALL ARTICLES

NEWSLETTER

January 2018 Massive Bio Newsletter
J.P. Morgan Healthcare Conference Insights January 2018 Newsletter

Hello everyone! Another J.P. Morgan Healthcare Conference has come and gone. Overall, it was chaotic but productive for Massive Bio. There were no game changing learning experiences for our core which is precision oncology informatics services, maybe because we live and breathe this space every day. 

VIEW ALL ARTICLES
Stay in Touch with Us
To speak with a dedicated cancer care specialist, contact us by one of the options listed below:
PLEASE FILL OUT FORM BELOW

X
Talk to Cancer Care Experts
Talk to Cancer Care Experts:
+1 (844) 627-7246
Top